Retatrutide FAERS Reports: What Adverse-Event Counts Can and Cannot Show
TL;DR: Public Citizen counted 26 FDA adverse-event reports on retatrutide in early 2026; voluntary reports cannot show incidence or cause.
What Did Public Citizen Report About Retatrutide?
In June 2026, the advocacy group Public Citizen published an investigation by its Health Research Group into the market for unapproved retatrutide. Using the FDA Adverse Event Reporting System (FAERS), it counted 10 retatrutide-related reports in 2025, four of which involved hospitalisation, and 26 in the first five months of 2026, of which eleven involved hospitalisation and three were described as life-threatening.[1] The report also tallied FDA warning letters sent to retatrutide sellers since 2024 and argued that enforcement has not slowed the market.[1]
Public Citizen is an advocacy organisation, and its framing is critical of FDA enforcement. We summarise its counts here as third-party reporting; we have not independently re-queried FAERS, and the figures should be read as that group's tally on the date it was published.
Counts, not rates. A rise from 10 to 26 reports describes more voluntary submissions. It does not tell us how many people used any product, which product it was, or whether it caused any event.
What Is FAERS and How Does Voluntary Reporting Work?
FAERS is the FDA's database of adverse-event, medication-error and product-quality submissions. Reports come from manufacturers (who are legally required to forward what they receive) and from clinicians and members of the public who file voluntarily. The FDA is explicit about the limits: a report does not prove that a product caused an event, the data may be incomplete, inaccurate, duplicated or unverified, and the database cannot be used to calculate how often an event occurs in the population.[2]
Those limits matter more for an unapproved molecule than for a licensed drug. A licensed product has a defined formulation, a known manufacturer and a label, so a report can be linked to a specific, characterised product. A vial sold as “retatrutide” outside any regulated channel may differ from its label in identity, purity or quantity, which is why independent analytical testing of such products is a recurring theme in third-party reporting.[3]
How Do FAERS Counts Differ From Poison-Centre Data?
Two datasets are often quoted together in coverage of retatrutide, and they measure different things. Poison-centre figures count calls to regional centres about exposures; our earlier coverage of America’s Poison Centers data, reported by Medscape on 26 June 2026, describes an average of roughly 95 retatrutide exposure reports per month in the first four months of 2026.[3] FAERS, by contrast, records written reports submitted to the FDA. A single event can appear in both, in one, or in neither, so the series cannot be summed or compared directly.
FAERS (FDA)
Voluntary and mandatory written reports; free-text narratives; no denominator; duplicates possible.
Poison-centre exposure calls
Telephone reports to regional centres; call-based coding; no confirmation of product identity or purity.
Controlled trial safety data
Pre-specified, adjudicated adverse-event collection with a placebo comparator and a known study drug — the only one of the three that can support a rate.
Where Does Retatrutide Stand as a Licensed Drug?
Retatrutide is an investigational GIP/GLP-1/glucagon triple agonist in Eli Lilly’s Phase 3 TRIUMPH programme. It is not approved by the FDA, the MHRA or any other regulator. Lilly has said it is available only to participants in its clinical trials, and BioPharma Dive reported in 2026 that the company plans to seek FDA approval in the first quarter of 2027, after saying it needed more time to assemble manufacturing and quality-control data.[4] Our guide to the filing timeline sets out that reporting in more detail.
Because no licensed product exists, any FAERS report naming retatrutide concerns either trial supply or an unverified product from outside regulated channels. For the enforcement side of the story, see our summary of FDA warning letters to peptide sellers, and for the poison-centre figures, our retatrutide poison-centre data guide.
What Should Researchers Take From These Numbers?
For laboratory researchers, the practical lessons concern evidence quality rather than any finding about the molecule. First, treat spontaneous-report counts as hypothesis-generating signals only. Second, separate three categories that coverage often blurs: a licensed pharmaceutical in trials, unverified products sold outside any regulated channel, and a research reagent supplied for in vitro work with batch documentation. Third, when a source quotes a percentage change in reports, ask for the denominator and the period compared.
None of this changes retatrutide’s published trial record, which is peer-reviewed separately. Velox Peptides supplies retatrutide solely as an HPLC-verified research reagent; see the retatrutide research-grade listing for batch documentation.
Retatrutide reference material is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Public Citizen, Health Research Group. Retatrutide Report (investigation into unapproved retatrutide products, FAERS counts and FDA warning letters). June 2026. citizen.org · full report (PDF)
- U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS), description of data and limitations. fda.gov
- Medscape. Unapproved Retatrutide Use Challenges Clinicians. 26 June 2026. medscape.com
- BioPharma Dive. Lilly, with new data, to seek FDA approval of obesity drug retatrutide. 2026. biopharmadive.com
Frequently Asked Questions
How many FDA adverse-event reports mention retatrutide?
Public Citizen's June 2026 report, drawing on the FDA Adverse Event Reporting System, counted 10 retatrutide-related reports in 2025 and 26 in the first five months of 2026, eleven of the 2026 reports involving hospitalisation. These are voluntary submissions, so they do not establish incidence or causation.
Does a FAERS report prove a product caused harm?
No. FDA states that FAERS reports are not proof of causation, may be incomplete or duplicated, and cannot be used to calculate incidence. They are a signal-detection tool, not a rate.
Why are there FAERS reports for a drug that is not approved?
Reports can be filed about any product a person says they used, whether or not it is approved. Retatrutide remains an investigational molecule in Eli Lilly's Phase 3 programme, so reports about it relate to trial supply or to unverified products sold outside any regulated channel.
How is this different from poison-centre data?
Poison-centre figures count calls to regional centres about exposures; FAERS counts written reports to the FDA. The two systems overlap in purpose but not in method, so their numbers should not be added together or compared directly.
Is Velox Peptides' retatrutide a medicine?
No. Velox Peptides supplies retatrutide solely as an HPLC-verified in vitro research reagent for qualified laboratory use. It is not a medicine, is not approved by any regulator, and is not for human or veterinary use.